Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival.
Lara SchwiegerLauren M PostlewaitYi LiuStephanie JouSha YiLimin PengXiaoxian Li
Published in: Breast cancer research and treatment (2024)
Tumor expression of ER/PR/HER2 can differ between the PT and MET. Loss of ER/PR expression is common and may be related to worse survival. Routine assessment of MET tumor markers could inform prognosis and therapeutic decision-making.